Flutemetamol (18F) 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4301	765922-62-1

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

Flutemetamol (18F)
18F-Flutemetamol
flutemetamol F 18 injection
flutemetamol F 18
vizamyl
flutemetamol F18
flutemetamol F-18

used for PET imaging of brain fibrillar amyloid beta

Molecular weight: 273.32
Formula: C14H11FN2OS
CLOGP: 4.30
LIPINSKI: 0
HAC: 3
HDO: 2
TPSA: 45.15
ALOGS: -4.31
ROTB: 2

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Sept. 27, 2017	PMDA	Nihon Medi-Physics Co Ltd
Oct. 25, 2013	FDA	GE HEALTHCARE
Aug. 22, 2014	EMA	GE Healthcare AS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V09AX04	VARIOUS DIAGNOSTIC RADIOPHARMACEUTICALS CENTRAL NERVOUS SYSTEM Other central nervous system diagnostic radiopharmaceuticals
FDA MoA	N0000000205	Radiopharmaceutical Activity
MeSH PA	D003287	Contrast Media
MeSH PA	D064907	Diagnostic Uses of Chemicals
MeSH PA	D007202	Indicators and Reagents
MeSH PA	D019275	Radiopharmaceuticals
FDA EPC	N0000177914	Radioactive Diagnostic Agent
CHEBI has role	CHEBI:37336	radioactive imaging agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Positron emission tomography	indication	82918005

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.2	acidic
pKa2	3.58	Basic
pKa3	2.7	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
121.5mCi/30ML (4.05mCi/ML)	VIZAMYL	GE HEALTHCARE	N203137	Oct. 25, 2013	RX	INJECTABLE	INTRAVENOUS	7351401	Jan. 24, 2023	DIAGNOSTIC RADIOIMAGING
121.5mCi/30ML (4.05mCi/ML)	VIZAMYL	GE HEALTHCARE	N203137	Oct. 25, 2013	RX	INJECTABLE	INTRAVENOUS	8691185	Jan. 24, 2023	DIAGNOSTIC RADIOIMAGING
40.5mCi/10ML (4.05mCi/ML)	VIZAMYL	GE HEALTHCARE	N203137	Oct. 25, 2013	DISCN	INJECTABLE	INTRAVENOUS	7351401	Jan. 24, 2023	DIAGNOSTIC RADIOIMAGING
40.5mCi/10ML (4.05mCi/ML)	VIZAMYL	GE HEALTHCARE	N203137	Oct. 25, 2013	DISCN	INJECTABLE	INTRAVENOUS	8691185	Jan. 24, 2023	DIAGNOSTIC RADIOIMAGING
121.5mCi/30ML (4.05mCi/ML)	VIZAMYL	GE HEALTHCARE	N203137	Oct. 25, 2013	RX	INJECTABLE	INTRAVENOUS	7270800	Sept. 3, 2025	DIAGNOSTIC RADIOIMAGING
40.5mCi/10ML (4.05mCi/ML)	VIZAMYL	GE HEALTHCARE	N203137	Oct. 25, 2013	DISCN	INJECTABLE	INTRAVENOUS	7270800	Sept. 3, 2025	DIAGNOSTIC RADIOIMAGING

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Amyloid beta A4 protein	Unclassified	P05067	A4_HUMAN		Ki	9.15		CHEMBL

External reference:

ID	Source
D10231	KEGG_DRUG
4038255	VANDF
C2983948	UMLSCUI
CHEBI:76611	CHEBI
CHEMBL2042122	ChEMBL_ID
DB09151	DRUGBANK_ID
C581552	MESH_SUPPLEMENTAL_RECORD_UI
15950376	PUBCHEM_CID
1486025	RXNORM
206870	MMSL
29778	MMSL
d08135	MMSL
016452	NDDF
456996004	SNOMEDCT_US
456997008	SNOMEDCT_US
9169	INN_ID
L49M066S0O	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Vizamyl	HUMAN PRESCRIPTION DRUG LABEL	1	17156-067	SOLUTION	4.05 mCi	INTRAVENOUS	NDA	26 sections
Vizamyl	HUMAN PRESCRIPTION DRUG LABEL	1	17156-067	SOLUTION	4.05 mCi	INTRAVENOUS	NDA	26 sections
Vizamyl	HUMAN PRESCRIPTION DRUG LABEL	1	17156-067	SOLUTION	4.05 mCi	INTRAVENOUS	NDA	26 sections
Vizamyl	HUMAN PRESCRIPTION DRUG LABEL	1	17156-067	SOLUTION	4.05 mCi	INTRAVENOUS	NDA	26 sections